The pivotal BHV4157-206-RWE study evaluating Biohaven's pipeline candidate, troriluzole, for treating spinocerebellar ataxia meets its primary endpoint.
were able to achieve an improved change from baseline of the modified functional Scale for the Assessment and Rating of Ataxia [f-SARA] at 3 years with all genotypes of these patients. Such an ...
in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) at 3 years in all study ...
Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), today announced positive topline results from pivotal Study BHV4157-206-RWE (NCT06529146) demonstrating the efficacy of troriluzole on the mean ...
MANILA, Philippines — Vice President Sara Duterte appeared at yesterday’s hearing of the House committee on good government and public accountability, but refused to take her oath and ...
Full-time: Celtic 5-1 Slovan Bratislava 🏆 Maeda could easily have had Celtic two ahead before Scales netted. The winger fired over inside four minutes after being played in by Alistair Johnston ...